Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Rhea-AI Summary

Evogene (NASDAQ: EVGN) announced on February 10, 2026 an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform using Google Cloud Vertex AI. The phase aims to accelerate and scale small-molecule discovery, shorten design–make–test–analyze cycles, and enable parallel molecular exploration.

The move follows a prior October 2024 milestone that built a generative AI foundation model now core to ChemPass AI™. Evogene said the partnership could broaden offerings, improve speed and cost structure, and make some tools available via Google Cloud Marketplace.

News Market Reaction – EVGN

-7.34% 12.1x vol

8 alerts

-7.34% News Effect

+40.7% Peak Tracked

-16.8% Trough Tracked

-$753K Valuation Impact

$9.50M Market Cap

12.1x Rel. Volume

On the day this news was published, EVGN declined 7.34%, reflecting a notable negative market reaction. Argus tracked a peak move of +40.7% during that session. Argus tracked a trough of -16.8% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $753K from the company's valuation, bringing the market cap to $9.50M at that time. Trading volume was exceptionally heavy at 12.1x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $1.09 52-week range: $0.93–$2.42 Market cap: $9,415,648 +5 more

8 metrics

Current price $1.09 Prior close before Google Cloud AI collaboration release

52-week range $0.93–$2.42 52-week low and high for EVGN

Market cap $9,415,648 Equity value prior to expanded collaboration announcement

Volume vs. average 75,565 vs. 705,543 Today’s volume vs. 20-day average; relative volume 0.11

Global castor oil market USD 2.4 billion Casterra/Fantini release cited 2025 market value

Castor oil 2030 forecast USD 3.09 billion Casterra/Fantini release projected 2030 market

Castor oil CAGR 5.20% CAGR Projected growth rate to 2030 from Casterra/Fantini release

Experience in biotech 15 years Dr. Olga Nissan’s experience noted in Dec 30, 2025 release

Market Reality Check

Price: $0.7838 Vol: Volume 75,565 is well bel...

low vol

$0.7838 Last Close

Volume Volume 75,565 is well below the 20-day average of 705,543 (relative volume 0.11), suggesting limited pre-news positioning. low

Technical Shares at $1.09 are trading below the 200-day MA of $1.21 and sit about 55% under the $2.42 52-week high, though above the $0.93 52-week low.

Peers on Argus

EVGN was modestly higher (+0.93%) while key biotech peers showed mixed moves, wi...

EVGN was modestly higher (+0.93%) while key biotech peers showed mixed moves, with several declines (e.g., ERNA -11.58%, LYRA -16.94%) and one notable gainer (MBIO +8.26%). With no peers in the momentum scanner and no same-day peer headlines, the move appears stock-specific rather than part of a sector-wide AI or biotech rotation.

Historical Context

5 past events · Latest: Feb 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Advisory board appointments	Positive	+0.9%	Added two academic experts to strengthen ChemPass AI scientific leadership.
Feb 04	Oncology licensing deal	Positive	+4.8%	Biomica licensed BMC128 globally to Lishan with milestones and royalties.
Jan 07	Neurology collaboration	Positive	-0.9%	Teamed with Unravel Biosciences on first-in-class demyelination therapy.
Dec 30	VP business development hire	Positive	-3.2%	Appointed experienced BD leader to scale ChemPass AI collaborations.
Nov 11	Agricultural partnership	Positive	+4.6%	Casterra–Fantini deal to mechanize scalable commercial castor farming.

Pattern Detected

Recent EVGN news skew positive (partnerships, licensing, management hires), with three of five events seeing price moves aligned with the constructive tone and two showing divergence where upbeat announcements coincided with short-term selling.

Recent Company History

Over the last few months, Evogene has reported several strategic milestones. On Nov 11, 2025, subsidiary Casterra announced an agricultural mechanization partnership, followed by multiple financial reporting 6-Ks. In late Dec 2025 and Feb 2026, Evogene strengthened its business development and scientific leadership around ChemPass AI™. Early Feb 2026 also brought an oncology licensing deal via Biomica. Today’s expanded Google Cloud AI collaboration fits this pattern of leveraging ChemPass AI across pharma and ag-tech partnerships.

Market Pulse Summary

The stock moved -7.3% in the session following this news. A negative reaction despite an expanded Go...

Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite an expanded Google Cloud collaboration would fit prior instances where positive strategic updates, including new leadership hires and collaborations, coincided with short-term selling. This could reflect broader caution toward small-cap biotech or concerns about near-term funding and execution risk. Future assessments may focus on whether the AI-agent integration translates into concrete partner deals and milestones that help reshape sentiment.

AI-generated analysis. Not financial advice.

The new collaboration is expected to accelerate, scale and advance small-molecule discovery and optimization for pharmaceutical and agricultural products

REHOVOT, Israel, Feb. 10, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational chemistry company focused on AI-driven small-molecule design for the pharmaceutical and agricultural industries, today announced an expanded phase of its collaboration with Google Cloud. Under this new phase, the collaboration will focus on developing and integrating advanced AI Agents into Evogene's ChemPass AI™ platform, its proprietary engine for small-molecule discovery and optimization, using Google Cloud's Vertex AI platform. The goal is to increase the speed, precision, and efficiency of identifying and optimizing small molecules for drug and ag-chemical development.

This announcement marks the second major milestone in the partnership between Evogene and Google Cloud, following the successful collaboration announced in October 2024. The initial phase focused on building a generative AI foundation model that now serves as a core component of ChemPass AI™. This powerful capability drove Evogene's recent collaborations, and the addition of our new agent technology positions the company to broaden its offering and accelerate future partnerships.

AI agents represent a new generation of artificial intelligence systems that can independently plan, reason, and execute complex, multi-step scientific workflows. When integrated into ChemPass AI™, these agents are designed to automate and scale key discovery processes, enable large-scale parallel molecular exploration, shorten design–make–test–analyze cycles, and improve the accuracy and success rate of designing small-molecule based products.

These capabilities directly support Evogene's core objective: identifying high-quality small molecules that meet multiple, stringent criteria required to become commercially viable product candidates. The expanded collaboration is expected to further strengthen Evogene's position as a leader in next-generation molecular design for both pharmaceutical and agricultural markets.

Boaz Maoz, Managing Director, Google Cloud Israel, commented:
"This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries."

Ofer Haviv, President and CEO of Evogene, said: "Evogene is pleased to further expand its collaboration with Google Cloud. The integration of AI agents into ChemPass AI™ is expected to improve our speed, cost structure, and ability to run multiple discovery programs in parallel. We are also excited about the potential to make parts of our real-world innovation tools globally accessible through Google Cloud Marketplace. This collaboration marks for us a shift from AI models to autonomous discovery, as ChemPass AI™ enters a new phase of scale and execution."

About Evogene Ltd.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.

At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.

Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation".

Learn more at: www.evogene.com.

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when it discusses the success of the collaboration to increase the speed, precision, and efficiency of identifying and optimizing small molecules for drug and ag-chemical development, the success of Evogene to broaden its offering and accelerate future partnerships, the integration of AI agents into ChemPass AI™ which is expected to result in automate and scale key discovery processes, enable large-scale parallel molecular exploration, shorten design–make–test–analyze cycles, and improve the accuracy and success rate of designing small molecules based products and Evogene's position as a leader in next-generation molecular design for both pharmaceutical and agricultural markets. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel and Hamas and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Relations Contact:
Email: ir@evogene.com
Tel: +972-8-9311901

Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg 

 

View original content:https://www.prnewswire.com/news-releases/evogene-announces-expanded-collaboration-with-google-cloud-to-integrate-ai-agents-into-chempass-ai-302683508.html

SOURCE Evogene

FAQ

What will the Evogene (EVGN) and Google Cloud expansion deliver for ChemPass AI?

It will integrate advanced AI agents to automate and scale discovery workflows. According to Evogene, agents on Vertex AI aim to speed molecular design, enable large-scale parallel exploration, and shorten design–make–test–analyze cycles for drug and ag-chemical programs.

How does the February 10, 2026 Evogene (EVGN) update differ from the October 2024 collaboration?

The new phase adds autonomous AI agent capabilities beyond the foundation model. According to Evogene, October 2024 built a generative AI foundation model; the 2026 expansion focuses on agent-driven execution and scaling of discovery workflows on Vertex AI.

Will Evogene (EVGN) make ChemPass AI tools available on Google Cloud Marketplace?

Evogene indicated parts of its real-world innovation tools may be offered via Google Cloud Marketplace. According to Evogene, this could increase accessibility, allowing broader customer access to select ChemPass AI capabilities through Google Cloud.

What practical benefits does Evogene (EVGN) expect from integrating AI agents into ChemPass AI?

Evogene expects faster, more precise small-molecule identification and lower discovery costs. According to Evogene, agents are designed to improve accuracy and success rates while enabling parallel programs and reducing cycle times in discovery workflows.

How might the Evogene (EVGN) and Google Cloud integration affect future partnerships or programs?

The company expects the agent technology to broaden offerings and accelerate collaborations. According to Evogene, integrating agents into ChemPass AI strengthens its platform position and supports scaling of future drug and agricultural discovery partnerships.